Evaluation of enzyme immunoassay using a recombinant envelope protein expressed in insect cells for serological confirmation of HTLV-I infection.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Evaluation of enzyme immunoassay using a recombinant envelope protein expressed in insect cells for serological confirmation of HTLV-I infection.

AIDS Res Hum Retroviruses. 1992 Nov;8(11):1857-61. Unique Identifier : AIDSLINE MED/93143994
Yamashita K; Maekawa M; Mitani K; Wakamiya M; Ogino T; Miyamura K; Baba K; Yamamoto Y; Nyunoya H; Shimotohno K; et al; AIDS Research Center, National Institute of Health, Tokyo, Japan.

Abstract: A recombinant human T-lymphotropic virus type I (HTLV-I) envelope protein expressed in insect cells using a recombinant baculovirus was employed as the antigen in an enzyme immunoassay (renvEIA). Peripheral blood samples were obtained from asymptomatic carriers or healthy individuals. Plasma was tested for HTLV-I antibody by renvEIA, particle agglutination, and Western immunoblot (WB), and lymphocyte DNA was tested for HTLV-I proviral DNA amplification by polymerase chain reaction (PCR). Of 61 people aged 9 months or older, 23 were positive (gag+, env+) and 19 others were in the indeterminate category (gag+, env-) when their WB results were interpreted according to the WHO-proposed criteria. Thirty-seven cases, including all of the WB+ cases and 14 of 19 WB indeterminate cases, were positive by renvEIA. In 34 of 37 renvEIA-positive cases, the presence of long terminal repeat (LTR) and tax/rex region of HTLV-I proviral DNA was detected by polymerase chain reaction (PCR) and following Southern blot hybridization. Thus, renvEIA would be a useful supplemental assay to confirm the presence of HTLV-I antibody in HTLV-I asymptomatic carriers.

Keywords: Adolescence Adult Antigens, Viral/IMMUNOLOGY Base Sequence Child Child, Preschool Comparative Study DNA, Viral/ANALYSIS Female Gene Products, env/*IMMUNOLOGY Human HTLV-I Antibodies/*ANALYSIS HTLV-I Infections/*DIAGNOSIS *Immunoenzyme Techniques/STANDARDS Infant Male Middle Age Molecular Sequence Data Polymerase Chain Reaction Pregnancy Proviruses/GENETICS Recombinant Proteins/IMMUNOLOGY Support, Non-U.S. Gov't JOURNAL ARTICLE
930530
M9350973

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .